NCT06128213View on ClinicalTrials.gov

NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 31, 2024

Primary Completion Date

June 30, 2024

Study Completion Date

September 30, 2024

Conditions
Urinary Tract InfectionsPyelonephritis
Interventions
DRUG

NRX101 (a fixed dose combination of D-cycloserine (DCS) and lurasidone HCl (lurasidone))

oral NRX-101 (a fixed dose combination of 487.5 mg D-cycloserine (DCS) and 16.5 mg lurasidone HCl (lurasidone) twice daily for 10 days

Sponsors

Lead Sponsor

NeuroRx, Inc.
All Listed Sponsors
lead

NeuroRx, Inc.

INDUSTRY